{"id":"W4405043434","doi":"10.1182/blood-2024-200701","title":"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary; Foothills Medical Centre; University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Chemoimmunotherapy; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Interim analysis; Fludarabine; Leukemia; Randomized controlled trial; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262265,0.0004080772,0.001974278,0.00030198,0.0001153608,0.00009261098,0.0004797778,0.0002188837,0.0001939038],"category_scores_gemma":[0.0003713008,0.0002187429,0.0004905782,0.001144288,0.0004268464,0.00013034,0.0001223983,0.0001580256,0.000005128686],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.07885749,"about_ca_system_score_gemma":0.05206311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003035274,"about_ca_topic_score_gemma":0.00120393,"domain_scores_codex":[0.9970379,0.0001710031,0.00112238,0.0006127919,0.0005986704,0.000457185],"domain_scores_gemma":[0.9966478,0.001553603,0.000421107,0.001018588,0.0002378839,0.0001210135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9706031,0.001559622,0.000002931261,0.000702223,0.01618216,0.00003881731,0.001221034,0.001231559,0.003765126,0.00005246421,0.00004914791,0.004591819],"study_design_scores_gemma":[0.5986878,0.009765439,8.832719e-7,0.0004366188,0.009666821,0.00002648517,0.00006539714,0.3531182,0.02746779,0.000002784352,0.0006297061,0.0001320737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850712,0.003183461,0.001274721,0.00007898628,0.0004528277,0.009588953,0.0001857058,0.00006075825,0.0001033926],"genre_scores_gemma":[0.9946916,0.001351186,0.0005838846,0.00002577304,0.000297287,0.001622359,0.000265844,0.00008115933,0.001080942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3719153,"threshold_uncertainty_score":0.9533108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0857842112642104,"score_gpt":0.4075480686450218,"score_spread":0.3217638573808114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}